

October 24, 2018

Sawai Pharmaceutical Co., Ltd.

Upsher-Smith Laboratories, LLC

**UPSHER-SMITH LAUNCHES GENERIC VERSION OF ONFI® (CLOBAZAM), CIV  
IN TABLETS AND ORAL SUSPENSIONS DOSAGE FORMS**

Maple Grove, MN –October 23, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) announced the launch of Clobazam Tablets, CIV, 10 and 20 mg and Clobazam Oral Suspension, CIV, 2.5 mg/mL (the branded product: Onfi®\*).

Clobazam Tablets, CIV, 10 and 20 mg, and Clobazam Oral Suspension, CIV, 2.5 mg/mL are indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

The clobazam tablet market had U.S. sales of approximately \$594 million for the 12 months ending August, 2018, and the clobazam oral suspension market had U.S. sales of approximately \$255 million for the 12 months ending August 2018 according to IQVIA.

\* Onfi is a registered trademark of Lundbeck.

**About Upsher-Smith**

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. As we approach our 100<sup>th</sup> year in business, we enter a new ambitious era that has been accelerated by our 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Together, we seek to deliver the best value for our stakeholders, and most importantly, do more good for the patients we serve. For more information, visit <https://www.upsher-smith.com/>

---

◆ Contact information ◆

PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.

E-mail : [koho@sawai.co.jp](mailto:koho@sawai.co.jp)